Limits...
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, Malavasi N, Depenni R, Zironi S, Del Giovane C, Luppi G, Conte PF - Br. J. Cancer (2010)

Bottom Line: Twenty-nine (19.9%) and 33 patients (19.2%) had an EGFR/nuclei ratio >2.9 and CEP7 polisomy >50% respectively; 28 patients (19.2%) had a KRAS mutation.Neither EGFR GCN nor KRAS status was statistically correlated to TRG. 5-year DFS and OS were 63.3 and 71.5%, respectively, and no significant relation with EGFR GCN or KRAS status was found.Our data show that EGFR GCN and KRAS status are not prognostic factors in LARC treated with preoperative chemoradiation.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Department of Oncology, Hematology and Respiratory Disease, University Hospital, University of Modena and Reggio Emilia, Via del Pozzo, 71, Modena-41100, Italy. carmelo.bengala@unimore.it

ABSTRACT

Background: Epidermal growth factor receptor (EGFR), evaluated by immunohistochemistry, has been shown to have prognostic significance in patients with colorectal cancer. Gene copy number (GCN) of EGFR and KRAS status predict response and outcome in patients treated with anti-EGFR therapy, but their prognostic significance in colorectal cancer patients is still unclear.

Methods: We have retrospectively reviewed the baseline EGFR GCN, KRAS status and clinical outcome of 146 locally advanced rectal cancer (LARC) patients treated with preoperative chemoradiotherapy. Pathological response evaluated by Dworak's tumour regression grade (TRG), disease-free survival (DFS) and overall survival (OS) were analysed.

Results: Tumour regression grade 4 and TRG3-4 were achieved in 14.4 and 30.8% of the patients respectively. Twenty-nine (19.9%) and 33 patients (19.2%) had an EGFR/nuclei ratio >2.9 and CEP7 polisomy >50% respectively; 28 patients (19.2%) had a KRAS mutation. Neither EGFR GCN nor KRAS status was statistically correlated to TRG. 5-year DFS and OS were 63.3 and 71.5%, respectively, and no significant relation with EGFR GCN or KRAS status was found.

Conclusion: Our data show that EGFR GCN and KRAS status are not prognostic factors in LARC treated with preoperative chemoradiation.

Show MeSH

Related in: MedlinePlus

Disease-free survival according to the tumour regression grade.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2965865&req=5

fig2: Disease-free survival according to the tumour regression grade.

Mentions: At a median follow-up of 4.45 years (range 0.29–10.6), median DFS was 8 years (range 0.27–10.6) (Figure 1). The 5- and 10-year DFS were 63.6 and 39.8% respectively. The 5-year DFS was 77% for the patients with TRG3–4 and 58% for the patients with TRG0–2 (HR, 0.36; 95% CI: 0.18–0.74; P=0.005; Figure 2). The 5-year DFS was 64.2 and 62.2% for patients with low vs high EGFR/nuclei respectively (HR, 0.99; 95% CI: 0.51–1.94; P=0.99); 67.2 and 51.1% for patients with low vs high CEP7 polisomy respectively (HR, 1.43; 95% CI: 0.78–2.60; P=0.24); 64.7 and 61.3% for patients with wild-type vs mutated KRAS respectively (HR, 0.94; 95% CI: 0.49–1.83; P=0.86).


Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, Malavasi N, Depenni R, Zironi S, Del Giovane C, Luppi G, Conte PF - Br. J. Cancer (2010)

Disease-free survival according to the tumour regression grade.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2965865&req=5

fig2: Disease-free survival according to the tumour regression grade.
Mentions: At a median follow-up of 4.45 years (range 0.29–10.6), median DFS was 8 years (range 0.27–10.6) (Figure 1). The 5- and 10-year DFS were 63.6 and 39.8% respectively. The 5-year DFS was 77% for the patients with TRG3–4 and 58% for the patients with TRG0–2 (HR, 0.36; 95% CI: 0.18–0.74; P=0.005; Figure 2). The 5-year DFS was 64.2 and 62.2% for patients with low vs high EGFR/nuclei respectively (HR, 0.99; 95% CI: 0.51–1.94; P=0.99); 67.2 and 51.1% for patients with low vs high CEP7 polisomy respectively (HR, 1.43; 95% CI: 0.78–2.60; P=0.24); 64.7 and 61.3% for patients with wild-type vs mutated KRAS respectively (HR, 0.94; 95% CI: 0.49–1.83; P=0.86).

Bottom Line: Twenty-nine (19.9%) and 33 patients (19.2%) had an EGFR/nuclei ratio >2.9 and CEP7 polisomy >50% respectively; 28 patients (19.2%) had a KRAS mutation.Neither EGFR GCN nor KRAS status was statistically correlated to TRG. 5-year DFS and OS were 63.3 and 71.5%, respectively, and no significant relation with EGFR GCN or KRAS status was found.Our data show that EGFR GCN and KRAS status are not prognostic factors in LARC treated with preoperative chemoradiation.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Department of Oncology, Hematology and Respiratory Disease, University Hospital, University of Modena and Reggio Emilia, Via del Pozzo, 71, Modena-41100, Italy. carmelo.bengala@unimore.it

ABSTRACT

Background: Epidermal growth factor receptor (EGFR), evaluated by immunohistochemistry, has been shown to have prognostic significance in patients with colorectal cancer. Gene copy number (GCN) of EGFR and KRAS status predict response and outcome in patients treated with anti-EGFR therapy, but their prognostic significance in colorectal cancer patients is still unclear.

Methods: We have retrospectively reviewed the baseline EGFR GCN, KRAS status and clinical outcome of 146 locally advanced rectal cancer (LARC) patients treated with preoperative chemoradiotherapy. Pathological response evaluated by Dworak's tumour regression grade (TRG), disease-free survival (DFS) and overall survival (OS) were analysed.

Results: Tumour regression grade 4 and TRG3-4 were achieved in 14.4 and 30.8% of the patients respectively. Twenty-nine (19.9%) and 33 patients (19.2%) had an EGFR/nuclei ratio >2.9 and CEP7 polisomy >50% respectively; 28 patients (19.2%) had a KRAS mutation. Neither EGFR GCN nor KRAS status was statistically correlated to TRG. 5-year DFS and OS were 63.3 and 71.5%, respectively, and no significant relation with EGFR GCN or KRAS status was found.

Conclusion: Our data show that EGFR GCN and KRAS status are not prognostic factors in LARC treated with preoperative chemoradiation.

Show MeSH
Related in: MedlinePlus